021-51111890
购物车（）
sales@molnova.cn
Cl-C6-PEG4-O-CH2COOH
CAS No. 1799506-30-1
Cl-C6-PEG4-O-CH2COOH ( —— )
产品货号. M33556 CAS No. 1799506-30-1
Cl-C6-PEG4-O-CH2COOH (PROTAC Linker 4) 是一种 PROTAC linker，属于 PEG 类。Cl-C6-PEG4-O-CH2COOH 可用于合成含氯烷烃的 PROTACs (HaloPROTACs)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥177 | 有现货 |
|
| 10MG | ￥245 | 有现货 |
|
| 25MG | ￥384 | 有现货 |
|
| 50MG | ￥600 | 有现货 |
|
| 100MG | ￥893 | 有现货 |
|
| 500MG | ￥2682 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Cl-C6-PEG4-O-CH2COOH
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Cl-C6-PEG4-O-CH2COOH (PROTAC Linker 4) 是一种 PROTAC linker，属于 PEG 类。Cl-C6-PEG4-O-CH2COOH 可用于合成含氯烷烃的 PROTACs (HaloPROTACs)。
-
产品描述Cl-C6-PEG4-O-CH2COOH (PROTAC Linker 4) is a PEG-based PROTAC linker can be used in the synthesis of chloroalkane-containing PROTACs (HaloPROTACs).
-
体外实验PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number1799506-30-1
-
分子量370.87
-
分子式C16H31ClO7
-
纯度>98% (HPLC)
-
溶解度In Vitro:?Ethanol 中的溶解度 : 100 mg/mL (269.64 mM; 超声助溶) DMSO 中的溶解度 : 100 mg/mL (269.64 mM; 超声助溶 )
-
SMILESC(OCCOCCOCCCCCCCl)COCCOCC(O)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
RC-3095 (TFA)
一种选择性蛙皮素 (bombesin)/胃泌素 (gastrin) 释放肽受体拮抗剂。RC-3095 TFA 作用于关节炎小鼠，通过减少胃氧化损伤来发挥保护作用。
-
Quercetin-3-O-D-gluc...
Quercetin-3-OD-glucosyl]-(1-2)-L-rhamnoside 是舒血宁中药注射液的主要抗氧化剂。
-
Chitinase, Serratia ...
Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer).
